LIN:NASDAQ

Linde plc

Data as of 2026-03-09 - not real-time

$483.62

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Linde plc (LIN) is trading at $483.62, comfortably above its 50‑day (≈$461.56) and 200‑day (≈$456.13) moving averages, but slightly under the 20‑day SMA (≈$488.90), indicating a short‑term pullback within a longer‑term bullish framework. The RSI sits at 51, suggesting neutral momentum, while the MACD histogram is negative and the signal line is deemed bearish, warning of possible near‑term downside pressure. Volatility over the past 30 days is elevated at roughly 21%, yet the stock’s beta of 0.58 points to lower systematic risk compared with the market. Recent earnings beat (adjusted EPS $4.20 vs. $4.18 consensus) and a 6% YoY revenue rise to $8.8 B underscore solid operational performance, but the full‑year 2026 guidance fell short of analyst expectations, prompting a modest pre‑market dip of over 2%. The DCF‑derived fair value of $134 suggests a stark undervaluation, yet market multiples (PE 33×, forward PE 24.8×, P/B 5.86×) are on the higher side, resulting in a modest upside estimate of ~6% from current levels. The dividend yield of 1.32% with a 41% payout ratio is supported by robust cash generation (free cash flow $4.79 B) and a strong balance sheet, indicating sustainability. Overall, the stock sits near a support zone around $444 and faces resistance near $511, with the technical picture mixed but fundamentals indicating a resilient, dividend‑paying growth blend.

Trading Recommendations

Short Term

< 1 year
hold
Conviction: 6/10

Key Factors

  • Guidance miss leading to recent price dip
  • Bearish MACD signal
  • Price hovering just below 20‑day SMA

Medium Term

1–3 years
buy
Conviction: 7/10

Key Factors

  • Consistent revenue and margin expansion
  • Modest upside potential (~6%) relative to current price
  • Sustainable dividend with strong cash flow

Long Term

> 3 years
buy
Conviction: 8/10

Key Factors

  • Global footprint across diversified end‑markets
  • Stable earnings and cash generation
  • Attractive dividend yield and low beta

Key Metrics & Analysis

Financial Health

Revenue Growth5.80%
Profit Margin20.30%
P/E Ratio33.1
ROE17.82%
ROA7.17%
Debt/Equity70.63
P/B Ratio5.9
Op. Cash Flow$10.4B
Free Cash Flow$4.8B

Technical Analysis

TrendBullish
RSI51.4
Support$444.02
Resistance$510.65
MA 20$488.90
MA 50$461.56
MA 200$456.13
MACDBearish
VolumeStable
Fear & Greed Index100

Valuation

Fair Value$134.21
Target Price$512.43
Upside/Downside5.96%
GradeFair
TypeBlend
Dividend Yield1.32%

Risk Assessment

Beta0.58
Volatility21.02%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.